Trial
NCT01739400
Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Actelion
Collaborators
—
Condition
Pulmonary Arterial Hypertension
Intervention
Macitentan 10 mg tablet, once daily.
Why stopped
Primary endpoint of parent study AC-055-305/MAESTRO (NCT01743001) not met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-16